Matthew Feinstein is a Cardiology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
251 E Huron St
Galter 3-150
Chicago, IL 606112908
Telephone
312-926-2253Provider last certified this registry record 12 Dec 2025.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk ASProgram year20256 payments$23,831openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year20255 payments$17,488openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
92.6%Statin24.5%Rosuvastatin Calcium54%Atorvastatin Calcium46%Part D≥30 patientsBeta blocker19%Metoprolol Succinate76%Carvedilol24%Part D≥30 patients+ 7 more classes in this area
Blood & clotting
7.4%P2Y12 inhibitor4.5%Clopidogrel61%Prasugrel Hcl39%Part D<11 patientsFactor Xa inhibitor2.9%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2020–2025 per NIH RePORTER. The latest:
- Integrated epidemiology of systemic and plaque-specific immunologic features of human atherosclerosis
Northwestern University
FY2025$788,083R01HL175893 - Integrated epidemiology of systemic and plaque-specific immunologic features of human atherosclerosis
Northwestern University at Chicago
FY2024$796,083R01HL175893 - Immunologic, Inflammatory, and Clinical contributors to HIV-Related Heart Failure with Preserved Ejection Fraction (HFpEF)
Northwestern University at Chicago
FY2024$707,690R01HL156792
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”